Nano cap Leap Therapeutics (LPTX -42.6%) plummets on a 10x surge volume in apparent response to its disclosure that it will “de-prioritize” further development of TRX518, its #2 candidate in Phase 2 development for solid tumors.
The company says the move will enable it to sharpen its focus on lead drug DKN-01, in Phase 2 development for gynecological cancers.
At the end of September, it had $10.1M in quick assets while operations consumed ($21.0M) during the first nine months of the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.